Dapagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor initially developed for the treatment of type 2 diabetes mellitus (T2DM), has demonstrated substantial cardiovascular benefits beyond glycemic control [3]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.